Macron visit to China comes at 'complex' time for EU-Beijing trade
What you need to know about the French President's visit
Stay updated with breaking news from Thomas Triomphe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
What you need to know about the French President's visit
Eva Schaefer-Jansen: find the slides to this earnings call on the Investors page of our website at sanofi.com.
SNY earnings call for the period ending December 31, 2022.
The Biologics License Application for nirsevimab as the first protective option against RSV for all infants has been accepted by the FDA.
FDA accepts nirsevimab application as first protective option against RSV disease for all infants Nirsevimab would be the first broadly protective option against RSV disease designed for all infants, if approvedNirsevimab delivered consistent protection of approximately 80% against medically attended RSV diseas...